{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:35:21Z","timestamp":1792852521694,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Fru Berta Kamprads Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>There is a lack of validated imaging biomarkers for prediction of response to peptide receptor radionuclide therapy (PRRT). The primary objective was to evaluate if tumour burden at baseline PET\/CT could predict treatment outcomes to PRRT with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-TATE. Secondary objectives were to evaluate if there was a correlation between tumour burden and mean tumour absorbed dose (AD) during first cycle, and if mean tumour AD or the relative change of tumour burden at first follow-up PET\/CT could predict progression free survival (PFS) or overall survival (OS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with gastroenteropancreatic neuroendocrine tumour (GEP-NET) treated with [<jats:sup>177<\/jats:sup>Lu]Lu-DOTA-TATE PRRT were retrospectively included. Tumour burden was quantified from [<jats:sup>68<\/jats:sup>\u00a0Ga]Ga-DOTA-TOC\/TATE PET\/CT-images at baseline and first follow-up and expressed as; whole-body somatostatin receptor expressing tumour volume (SRETVwb), total lesion somatostatin receptor expression (TLSREwb), largest tumour lesion diameter and highest SUVmax. The relative change of tumour burden was evaluated in three categories. Mean tumour AD was estimated from the first cycle of PRRT. PFS was defined as time from start of PRRT to radiological or clinical progression. OS was evaluated as time to death. Kaplan Meier survival curves and log-rank test were used to compare PFS and OS between different groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-one patients had a baseline PET\/CT\u2009&lt;\u20096\u00a0months before treatment and 25 had a follow-up examination. Median tumour burden was 132\u00a0ml (IQR 61\u2013302) at baseline and 71\u00a0ml (IQR 36\u2013278) at follow-up. Twenty-two patients had disease progression (median time to progression 17.2\u00a0months) and 9 patients had no disease progression (median follow-up 28.7\u00a0months). SRETVwb dichotomized by the median at baseline was not associated with longer PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.861) or OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.937). Neither TLSREwb, largest tumour lesion or SUVmax showed significant predictive value. There was a moderately strong correlation, however, between SUVmax and mean tumour AD r\u2009=\u20090.705, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, but no significant correlation between SRETVwb nor TLSREwb and mean tumour AD. An increase of SRETVwb, TLSREwb or largest tumour lesion at first follow-up PET\/CT was significantly correlated with shorter PFS\/OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tumour burden at baseline showed no predictive value of PFS\/OS after PRRT in this small retrospective study. An increase of tumour burden was predictive of worse outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41824-024-00210-y","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T23:02:58Z","timestamp":1723071778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Retrospective evaluation of the predictive value of tumour burden at baseline [68\u00a0Ga]Ga-DOTA-TOC or -TATE PET\/CT and tumour dosimetry in GEP-NET patients treated with PRRT"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9050-7889","authenticated-orcid":false,"given":"Anni","family":"G\u00e5lne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sundl\u00f6v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Enqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Sj\u00f6green Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Tr\u00e4g\u00e5rdh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"issue":"9","key":"210_CR1","first-page":"1259","volume":"60","author":"EA Aalbersberg","year":"2019","unstructured":"Aalbersberg EA, Huizing DMV, Walraven I, Veen BJ, Kulkarni HR, Singh A et al (2019) Parameters to predict progression-free and overall survival after peptide receptor radionuclide therapy: a multivariate analysis in 782 patients. J Nuclear Med Offic Publ Soc Nuclear Med 60(9):1259\u20131265","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"issue":"3","key":"210_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11154-020-09581-6","volume":"22","author":"M Albertelli","year":"2021","unstructured":"Albertelli M, Dotto A, Di Dato C, Malandrino P, Modica R, Versari A et al (2021) PRRT: identikit of the perfect patient. Rev Endocr Metab Disord 22(3):563\u2013579","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"210_CR3","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C et al (2017) Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 44(9):1588\u20131601","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"210_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13550-022-00901-2","volume":"12","author":"EA Carlsen","year":"2022","unstructured":"Carlsen EA, Lindholm K, Hindsholm A, G\u00e6de M, Ladefoged CN, Loft M et al (2022) A convolutional neural network for total tumor segmentation in [(64)Cu]Cu-DOTATATE PET\/CT of patients with neuroendocrine neoplasms. EJNMMI Res 12(1):30","journal-title":"EJNMMI Res"},{"issue":"12","key":"210_CR5","first-page":"614","volume":"44","author":"YH Chan","year":"2003","unstructured":"Chan YH (2003) Biostatistics 104: correlational analysis. Singapore Med J 44(12):614\u2013619","journal-title":"Singapore Med J"},{"issue":"5","key":"210_CR6","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","volume":"7","author":"DL Chan","year":"2017","unstructured":"Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A et al (2017) Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics 7(5):1149\u20131158","journal-title":"Theranostics"},{"issue":"9","key":"210_CR7","first-page":"1467","volume":"47","author":"M Cremonesi","year":"2006","unstructured":"Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G (2006) Dosimetry in Peptide radionuclide receptor therapy: a review. J Nuclear Med Offic Publ Soc Nuclear Med 47(9):1467\u20131475","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"issue":"1","key":"210_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41824-021-00116-z","volume":"5","author":"SC Ebbers","year":"2021","unstructured":"Ebbers SC, Heimgartner M, Barentsz MW, van Leeuwaarde RS, van Treijen MJC, Lam M, Braat A (2021) Gallium-68-somatostatin receptor PET\/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. Eur J Hybrid Imaging 5(1):22","journal-title":"Eur J Hybrid Imaging"},{"issue":"6","key":"210_CR9","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1097\/RLU.0b013e31823926e5","volume":"37","author":"S Ezziddin","year":"2012","unstructured":"Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G et al (2012) Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med 37(6):e141\u2013e147","journal-title":"Clin Nucl Med"},{"issue":"2","key":"210_CR10","first-page":"183","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Gr\u00fcnwald F et al (2014) Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nuclear Med Offic Publ Soc Nuclear Med 55(2):183\u2013190","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"issue":"9","key":"210_CR11","first-page":"1427","volume":"50","author":"M Gabriel","year":"2009","unstructured":"Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D et al (2009) 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nuclear Med Offic Publ Soc Nuclear Med 50(9):1427\u20131434","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"issue":"4","key":"210_CR12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2967\/jnumed.118.215376","volume":"60","author":"M Gabriel","year":"2019","unstructured":"Gabriel M, Nilica B, Kaiser B, Virgolini IJ (2019) Twelve-year follow-up after peptide receptor radionuclide therapy. J Nucl Med 60(4):524\u2013529","journal-title":"J Nucl Med"},{"issue":"1","key":"210_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41824-023-00172-7","volume":"7","author":"A G\u00e5lne","year":"2023","unstructured":"G\u00e5lne A, Enqvist O, Sundl\u00f6v A, Valind K, Minarik D, Tr\u00e4g\u00e5rdh E (2023) AI-based quantification of whole-body tumour burden on somatostatin receptor PET\/CT. Eur J Hybrid Imaging 7(1):14","journal-title":"Eur J Hybrid Imaging"},{"issue":"10","key":"210_CR14","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1002\/mp.16528","volume":"50","author":"J Gustafsson","year":"2023","unstructured":"Gustafsson J, Ljungberg M, Alm Carlsson G, Larsson E, Warfvinge CF, Asp P, Sj\u00f6green GK (2023) Averaging of absorbed doses: how matter matters. Med Phys 50(10):6600\u20136613","journal-title":"Med Phys"},{"issue":"9","key":"210_CR15","first-page":"1349","volume":"51","author":"AR Haug","year":"2010","unstructured":"Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B et al (2010) 68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nuclear Med Offic Publ Soc Nuclear Med 51(9):1349\u20131356","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"key":"210_CR16","doi-asserted-by":"publisher","first-page":"771912","DOI":"10.3389\/fmed.2021.771912","volume":"8","author":"J Hou","year":"2021","unstructured":"Hou J, Yang Y, Chen N, Chen D, Hu S (2021) Prognostic value of volume-based parameters measured by SSTR PET\/CT in neuroendocrine tumors: a systematic review and meta-analysis. Front Med 8:771912","journal-title":"Front Med"},{"issue":"2","key":"210_CR17","first-page":"177","volume":"56","author":"E Ilan","year":"2015","unstructured":"Ilan E, Sandstr\u00f6m M, Wassberg C, Sundin A, Garske-Rom\u00e1n U, Eriksson B et al (2015) Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nuclear Med Offic Publ Soc Nuclear Med 56(2):177\u2013182","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"issue":"7\u20138","key":"210_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1159\/000504001","volume":"110","author":"U Jahn","year":"2020","unstructured":"Jahn U, Ilan E, Sandstr\u00f6m M, Garske-Rom\u00e1n U, Lubberink M, Sundin A (2020) 177Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors. Neuroendocrinology 110(7\u20138):662\u2013670","journal-title":"Neuroendocrinology"},{"issue":"14","key":"210_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2217\/fon.14.139","volume":"10","author":"CB Johnbeck","year":"2014","unstructured":"Johnbeck CB, Knigge U, Kjaer A (2014) PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol 10(14):2259\u20132277","journal-title":"Future Oncol"},{"issue":"3","key":"210_CR20","doi-asserted-by":"publisher","first-page":"e212274","DOI":"10.1001\/jamanetworkopen.2021.2274","volume":"4","author":"ST Kipnis","year":"2021","unstructured":"Kipnis ST, Hung M, Kumar S, Heckert JM, Lee H, Bennett B et al (2021) Laboratory, clinical, and survival outcomes associated with peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. JAMA Netw Open 4(3):e212274","journal-title":"JAMA Netw Open"},{"issue":"3","key":"210_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A et al (2015) SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol 17(3):313\u2013318","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"210_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/cancers16010200","volume":"16","author":"H Lee","year":"2024","unstructured":"Lee H, Kipnis ST, Niman R, O\u2019Brien SR, Eads JR, Katona BW, Pryma DA (2024) Prediction of 177Lu-DOTATATE therapy outcomes in neuroendocrine tumor patients using semi-automatic tumor delineation on 68Ga-DOTATATE PET\/CT. Cancers 16(1):200","journal-title":"Cancers"},{"issue":"1","key":"210_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40658-021-00367-6","volume":"8","author":"V Liberini","year":"2021","unstructured":"Liberini V, De Santi B, Rampado O, Gallio E, Dionisi B, Ceci F et al (2021) Impact of segmentation and discretization on radiomic features in (68)Ga-DOTA-TOC PET\/CT images of neuroendocrine tumor. EJNMMI Phys 8(1):21","journal-title":"EJNMMI Phys"},{"issue":"6","key":"210_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1109\/TRPMS.2018.2860563","volume":"2","author":"M Ljungberg","year":"2018","unstructured":"Ljungberg M, Sj\u00f6green GK (2018) 3-D Image-based dosimetry in radionuclide therapy. IEEE Trans Radiat Plasma Med Sci 2(6):527\u2013540","journal-title":"IEEE Trans Radiat Plasma Med Sci"},{"issue":"2","key":"210_CR25","first-page":"236","volume":"65","author":"M Mileva","year":"2024","unstructured":"Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C et al (2024) Prediction of (177)Lu-DOTATATE PRRT outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: results from a prospective phase II LUMEN study. J Nuclear Med Offic Publ Soc Nuclear Med 65(2):236\u2013244","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"issue":"6","key":"210_CR26","doi-asserted-by":"publisher","first-page":"e13139","DOI":"10.1111\/jne.13139","volume":"34","author":"H Ohlsson","year":"2022","unstructured":"Ohlsson H, G\u00e5lne A, Tr\u00e4g\u00e5rdh E, Malmstr\u00f6m M, Sundl\u00f6v A, Almquist M (2022) Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET. J Neuroendocrinol 34(6):e13139","journal-title":"J Neuroendocrinol"},{"issue":"10","key":"210_CR27","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","volume":"62","author":"C Ortega","year":"2021","unstructured":"Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, Laidley D, Anconina R, Liu A, Metser U (2021) Quantitative <sup>68<\/sup>Ga-DOTATATE PET\/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with <sup>177<\/sup>Lu-DOTATATE. J Nuclear Med 62(10):1406\u20131414. https:\/\/doi.org\/10.2967\/jnumed.120.256727","journal-title":"J Nuclear Med"},{"issue":"4","key":"210_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1677\/ERC-08-0017","volume":"15","author":"U-F Pape","year":"2008","unstructured":"Pape U-F, Berndt U, M\u00fcller-Nordhorn J, B\u00f6hmig M, Roll S, Koch M et al (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4):1083\u20131097","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"210_CR29","first-page":"1014","volume":"61","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Van Binnebeek S, Vandecaveye V, Baete K, Vanbilloen H, Koole M et al (2020) Inflammation-based index and (68)Ga-DOTATOC PET-derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with (90)Y-DOTATOC. J Nuclear Med Offic Publ Soc Nuclear Med 61(7):1014\u20131020","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"issue":"6","key":"210_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1159\/000085237","volume":"80","author":"U Pl\u00f6ckinger","year":"2004","unstructured":"Pl\u00f6ckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW et al (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours: a consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80(6):394\u2013424","journal-title":"Neuroendocrinology"},{"issue":"12","key":"210_CR31","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G et al (2011) <sup>68<\/sup>Ga-DOTATOC Versus <sup>68<\/sup>Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med 52(12):1864\u20131870","journal-title":"J Nucl Med"},{"issue":"6","key":"210_CR32","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3390\/cancers15061861","volume":"15","author":"I Reccia","year":"2023","unstructured":"Reccia I, Pai M, Kumar J, Spalding D, Frilling A (2023) Tumour heterogeneity and the consequent practical challenges in the management of gastroenteropancreatic neuroendocrine neoplasms. Cancers 15(6):1861","journal-title":"Cancers"},{"issue":"4","key":"210_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/er.2002-0007","volume":"24","author":"JC Reubi","year":"2003","unstructured":"Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24(4):389\u2013427","journal-title":"Endocr Rev"},{"issue":"3","key":"210_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273\u2013282","journal-title":"Eur J Nucl Med"},{"key":"210_CR35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262069","author":"D Roth","year":"2021","unstructured":"Roth D, Gustafsson JR, Warfvinge CF, Sundl\u00f6v A, \u00c5kesson A, Tennvall J, Sj\u00f6green Gleisner K (2021) Dosimetric quantities of neuroendocrine tumors over treatment cycles with (177)Lu-DOTA-TATE. J Nuclear Med Offic Publ Soc Nuclear Med. https:\/\/doi.org\/10.2967\/jnumed.121.262069","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"key":"210_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.radonc.2019.09.003","volume":"141","author":"R Sharma","year":"2019","unstructured":"Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F et al (2019) (68)Ga-DOTATATE PET\/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol 141:108\u2013115","journal-title":"Radiother Oncol"},{"issue":"6","key":"210_CR37","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sj\u00f6green Gleisner","year":"2022","unstructured":"Sj\u00f6green Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C et al (2022) EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging 49(6):1778\u20131809","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"210_CR38","unstructured":"Sj\u00f6green Gleisner JG, Stenvall A, Roth D, Hindorf C, J\u00f6nsson L, Larsson E, Olsson T, Sundl\u00f6v A (2020) European Association of nuclear medicine october 22\u201330, Virtual. Eur J Nuclear Med Mol Imag. 376\u2013377"},{"issue":"3","key":"210_CR39","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/ERC-19-0400","volume":"27","author":"H Sorbye","year":"2020","unstructured":"Sorbye H, Kong G, Grozinsky-Glasberg S (2020) PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer 27(3):R67\u2013R77","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"210_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3906\/sag-1412-11","volume":"46","author":"\u00c7 Soydal","year":"2016","unstructured":"Soydal \u00c7, Peker A, \u00d6zkan E, K\u00fc\u00e7\u00fck \u00d6N, Kir MK (2016) The role of baseline Ga-68 DOTATATE positron emission tomography\/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE. Turk J Med Sci 46(2):409\u2013413","journal-title":"Turk J Med Sci"},{"issue":"10","key":"210_CR41","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","volume":"47","author":"J Strosberg","year":"2020","unstructured":"Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH et al (2020) Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging 47(10):2372\u20132382","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"210_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40658-018-0210-2","volume":"5","author":"A Sundl\u00f6v","year":"2018","unstructured":"Sundl\u00f6v A, Gustafsson J, Brolin G, Mortensen N, Hermann R, Bernhardt P et al (2018) Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy. EJNMMI Phys 5(1):12","journal-title":"EJNMMI Phys"},{"issue":"3","key":"210_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34(3):228\u2013252","journal-title":"Front Neuroendocrinol"},{"issue":"7","key":"210_CR44","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.121.262652","volume":"63","author":"P Thuillier","year":"2022","unstructured":"Thuillier P, Liberini V, Grimaldi S, Rampado O, Gallio E, Santi BD et al (2022) Prognostic value of whole-body PET volumetric parameters extracted from <sup>68<\/sup>Ga-DOTATOC PET\/CT in well-differentiated neuroendocrine tumors. J Nucl Med 63(7):1014\u20131020","journal-title":"J Nucl Med"},{"issue":"4","key":"210_CR45","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1053\/j.gastro.2017.11.008","volume":"154","author":"A Tirosh","year":"2018","unstructured":"Tirosh A, Papadakis GZ, Millo C, Hammoud D, Sadowski SM, Herscovitch P et al (2018) Prognostic utility of total (68)Ga-DOTATATE-avid tumor volume in patients with neuroendocrine tumors. Gastroenterology 154(4):998-1008.e1","journal-title":"Gastroenterology"},{"issue":"11","key":"210_CR46","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1007\/s00259-019-04455-9","volume":"46","author":"A Toriihara","year":"2019","unstructured":"Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G et al (2019) Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET\/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging 46(11):2244\u20132251","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"210_CR47","first-page":"204","volume":"55","author":"I Velikyan","year":"2014","unstructured":"Velikyan I, Sundin A, Sorensen J, Lubberink M, Sandstrom M, Garske-Roman U et al (2014) Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nuclear Med Offic Publ Soc Nuclear Med 55(2):204\u2013210","journal-title":"J Nuclear Med Offic Publ Soc Nuclear Med"},{"issue":"4","key":"210_CR48","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.18632\/oncotarget.12402","volume":"8","author":"RA Werner","year":"2016","unstructured":"Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S et al (2016) Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget 8(4):7039","journal-title":"Oncotarget"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00210-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-024-00210-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00210-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T23:03:11Z","timestamp":1723071791000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-024-00210-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["210"],"URL":"https:\/\/doi.org\/10.1186\/s41824-024-00210-y","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Swedish Ethical Review Authority (Dnr 2019-00411 and 2021-04197). As the study was retrospective, informed consent was not deemed necessary according to Regional Ethical Review Board. All procedures were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and contributed to the manuscript and gave approval for the final version and consent to submit this manuscript to EJNMMI Reports.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OE is board member and stockholder of Eigenvision AB, which is a company working with research and development in automated image analysis, computer vision and machine learning. The other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}